Karyopharm Therapeutics Inc. (NASDAQ:KPTI)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued on Wednesday. They presently have a $23.00 target price on the stock. HC Wainwright’s target price would indicate a potential upside of 118.22% from the stock’s previous close.
A number of other analysts also recently issued reports on KPTI. Zacks Investment Research downgraded Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. BidaskClub cut Karyopharm Therapeutics from a “sell” rating to a “strong sell” rating in a report on Monday, July 31st. Canaccord Genuity set a $18.00 target price on Karyopharm Therapeutics and gave the company a “buy” rating in a research note on Tuesday, August 8th. Jefferies Group LLC reissued a “buy” rating and set a $19.00 target price (up from $16.00) on shares of Karyopharm Therapeutics in a research note on Thursday, August 10th. Finally, ValuEngine cut Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 18th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $17.33.
Shares of Karyopharm Therapeutics (NASDAQ KPTI) opened at $10.54 on Wednesday. Karyopharm Therapeutics has a 12-month low of $7.48 and a 12-month high of $14.63.
Karyopharm Therapeutics (NASDAQ:KPTI) last issued its earnings results on Thursday, November 2nd. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative return on equity of 76.83% and a negative net margin of 67,267.47%. analysts expect that Karyopharm Therapeutics will post -2.58 EPS for the current fiscal year.
WARNING: This article was posted by Stock Observer and is the sole property of of Stock Observer. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.thestockobserver.com/2017/11/15/karyopharm-therapeutics-inc-kpti-coverage-initiated-at-hc-wainwright.html.
In other news, Director Mansoor Raza Mirza sold 2,882 shares of the firm’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $11.00, for a total value of $31,702.00. Following the completion of the sale, the director now owns 2,882 shares of the company’s stock, valued at approximately $31,702. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Christopher Brett Primiano sold 4,958 shares of Karyopharm Therapeutics stock in a transaction dated Tuesday, November 7th. The stock was sold at an average price of $11.25, for a total value of $55,777.50. The disclosure for this sale can be found here. Over the last quarter, insiders sold 15,653 shares of company stock worth $174,728. Company insiders own 14.71% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. Swiss National Bank increased its stake in shares of Karyopharm Therapeutics by 39.2% in the 2nd quarter. Swiss National Bank now owns 56,850 shares of the company’s stock valued at $514,000 after purchasing an additional 16,000 shares in the last quarter. Schwab Charles Investment Management Inc. increased its stake in shares of Karyopharm Therapeutics by 4.5% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 86,514 shares of the company’s stock valued at $1,111,000 after purchasing an additional 3,762 shares in the last quarter. Teachers Advisors LLC increased its stake in Karyopharm Therapeutics by 2.6% during the 2nd quarter. Teachers Advisors LLC now owns 431,350 shares of the company’s stock worth $3,904,000 after buying an additional 10,787 shares in the last quarter. Candriam Luxembourg S.C.A. increased its stake in Karyopharm Therapeutics by 16.4% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 510,000 shares of the company’s stock worth $5,600,000 after buying an additional 72,000 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Karyopharm Therapeutics by 7.8% during the 1st quarter. Geode Capital Management LLC now owns 168,770 shares of the company’s stock worth $2,167,000 after buying an additional 12,277 shares in the last quarter. Hedge funds and other institutional investors own 59.23% of the company’s stock.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.